# Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

> **NCT07279766** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Tor Biering-Sørensen** · enrollment: 285000 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** mRNA-1273 (Moderna COVID-19 vaccine)

## Key facts

- **NCT ID:** NCT07279766
- **Lead sponsor:** Tor Biering-Sørensen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-11
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 285000 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07279766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07279766, "Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07279766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*